Case Report

Toxic Encephalopathy and Methemoglobinemia after 5-Amino-2-(trifluoromethyl)pyridine Poisoning

Yiming Tao 1,2, Longke Shi 3, Jie Han 4, Xiangdong Jian 5,* and Yongsheng Li 1,2,*

1 Department of Intensive Care Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hankou, Wuhan 430030, China
2 Department of Emergency, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Hankou, Wuhan 430030, China
3 School of Public Health, Cheeloo College of Medicine, Shandong University, Jinan 250012, China
4 Department of Emergency, Qingdao Municipal Hospital, School of Medicine, Qingdao University, Qingdao 266071, China
5 Department of Poisoning and Occupational Diseases, Qilu Hospital of Shandong University, No. 107, Road Wenhuaixi, Jinan 250012, China
* Correspondence: jianxiangdongvip@vip.163.com (X.J.); ysli@tjh.tjmu.edu.cn (Y.L.)

Abstract: The aromatic amino compound 5-amino-2-(trifluoromethyl)pyridine acts as an intermediate in the synthesis of pharmaceutical products. However, the toxicity profile of this compound is sparse and no related poisoning events have been reported. Here, we report the case of a 35-year-old man who inhaled 5-amino-2-(trifluoromethyl)pyridine at work. After inhalation, the patient rapidly developed symptoms such as dizziness, fatigue, nausea, vomiting, chest tightness, and loss of consciousness. After admission, methemoglobinemia, hemolytic anemia, acute renal failure, and toxic encephalopathy occurred. Symptoms improved significantly after intravenous treatment with a low dose of methylene blue. This revealed that 5-amino-2-(trifluoromethyl)pyridine is toxic to the human body and can be absorbed through the respiratory tract, resulting in methemoglobinemia and toxic encephalopathy; thus, caution should be taken in industrial production.

Keywords: 5-amino-2-(trifluoromethyl)pyridine; methemoglobinemia; acute renal failure; toxic encephalopathy; magnetic resonance imaging

1. Introduction

The compound 5-amino-2-(trifluoromethyl)pyridine (C6H5F3N2; CAS Number: 106877-33-2) is a light yellow crystal. It causes severe eye, skin, and respiratory tract irritation as well as allergic skin reactions, or even death if ingested [1]. It acts as an intermediate in medicine and various chemical products [2,3]. However, to our knowledge, there are no systematic studies on the toxicology profile of 5-amino-2-(trifluoromethyl)pyridine, nor a relevant clinical profile. Here, we present a patient who was poisoned after inhaling 5-amino-2-(trifluoromethyl)pyridine and presented with methemoglobinemia, acute renal failure, and toxic encephalopathy.

2. Case Presentation

A 35-year-old male pharmaceutical laboratory technician with no relevant medical history had been working in a pharmaceutical plant for 10 years. The patient was assigned new tasks due to inadequate work force during the COVID-19 pandemic, thereby exposing him to 5-amino-2-(trifluoromethyl)pyridine for the first time. The patient did not often turn on the exhaust fan in the laboratory, did not wear respiratory protection equipment, and only wore rubber gloves. Moreover, the fume hood exhaust system ruptured, and vapor continued to leak into the laboratory during the extraction and recrystallization of 5-amino-2-(trifluoromethyl)pyridine. After three hours of continuous work, the patient
developed symptoms such as dizziness, suffocation, nausea, vomiting, and tingling in the eyes. After two hours of rest, the patient resumed duty. After an hour of working again, the patient went into a coma and was found by a colleague in that state presumably after two hours. He was rushed to a local hospital for treatment. The patient briefly regained consciousness on the way to the hospital and was back in a coma about 20 min later. In the local hospital, endotracheal intubation with mechanical ventilation was performed, and the peripheral oxygen saturation dropped to 88%. He was then transferred to our hospital for treatment ten hours after the initial coma.

On admission, the patient’s lips and nail beds were dark brown, and his blood was chocolate-colored. The main laboratory test results were as follows: pH, 7.23; partial pressure of oxygen (PO$_2$), 191 mmHg; oxygen saturation (SaO$_2$), 81.70%; methemoglobin (MetHb), 39.40%; blood lactate, 5.6 mmol/L (Table 1). After injecting 100 mg methylene blue (MB) intravenously, within half an hour, the blood gas analysis results were as follows: pH, 7.33; SaO$_2$, 93.30%; MetHb, 20.10%; blood lactate, 5.1 mmol/L. The nail bed and lips rapidly turned rosy. An hour later, the patient was given another intravenous bolus of 60 mg MB. Thereafter, 60 mg MB was administered intravenously daily for 4 days.

On the third day after onset, the patient recovered from coma. He had a mini-mental state examination (MMSE) score of 27, had no cognitive impairment, was off the ventilator, and was extubated. However, anuria, scleral jaundice, elevated indirect bilirubin, and a rapid decline in hemoglobin levels were observed on the same day. Based on this, the patient was judged to have hemolytic anemia. He was treated with dexamethasone 40 mg daily, continuous veno-venous hemofiltration (CVVH), and three plasmapheresis sessions (Figure 1). On the 10th day of onset, the urine output of the patient increased to 400 mL. Plasmapheresis and dexamethasone were discontinued, and CVVH therapy was continued.

During the course of treatment, the patient’s urine output increased. On the 19th day of onset, the patient recovered from coma. He had a mini-mental state examination (MMSE) score of 27, had no cognitive impairment, was off the ventilator, and was extubated. However, anuria, scleral jaundice, elevated indirect bilirubin, and a rapid decline in hemoglobin levels were observed on the same day. Based on this, the patient was judged to have hemolytic anemia. He was treated with dexamethasone 40 mg daily, continuous veno-venous hemofiltration (CVVH), and three plasmapheresis sessions (Figure 1). On the 10th day of onset, the urine output of the patient increased to 400 mL. Plasmapheresis and dexamethasone were discontinued, and CVVH therapy was continued.

During the course of treatment, the patient’s urine output increased. On the 19th day of onset, the patient’s urine output reached 2000 mL/day. However, at this time, his cognitive function declined, language comprehension and calculation ability declined, recent memory recall also decreased and he experienced mild disorientation, with a MMSE score of 19 and a Montreal cognitive assessment (MoCA) score of 15. The muscle strength of his appendages was graded at 5, with normal muscle tone and unremarkable tendon reflex and neck resistance, and a negative Babinski sign. Magnetic resonance imaging of the head revealed abnormal signals in the bilateral basal ganglia and corona radiata, and the patient was diagnosed with toxic encephalopathy. The lesion showed hypointense-to-
isointense signal on T1-weighted images, and hyperintense signal on T2-weighted images. Diffusion-weighted imaging (DWI), apparent diffusion coefficient (ADC) mapping and fluid-attenuated inversion-recovery (FLAIR) sequencing also demonstrated heterogeneous high signal (Figure 2).

**Figure 1.** Clinical course of a patient with 5-amino-2-(trifluoromethyl)pyridine poisoning. MB, methylene blue; CVVH, continuous veno-venous hemofiltration.

**Figure 2.** Images of a 35-year-old man exposed to 5-amino-2-(trifluoromethyl)pyridine. MRI 20 days after exposure showing abnormal signal intensity on (A) T1WI, (B) T2WI, (C) T2 FLAIR, (D) DWI and (E) T2WI of coronal in the bilateral cerebral hemispheres. T1WI, T1-weighted image; T2WI, T2-weighted image; DWI, diffusion-weighted imaging; FLAIR, fluid-attenuated inversion-recovery sequency.
The patient was given nerve growth factor to nourish the nerves, hyperbaric oxygen therapy, idebenone to improve cognitive function, and regular rehabilitation training. On the 25th day after onset, his laboratory test results were normal, prompting the patient’s discharge from the hospital and a continuation of citicoline sodium and idebenone at home. He continued rehabilitation training. Furthermore, 140 days after discharge from the hospital, the patient showed significant improvement in central nervous system symptoms and brain MRI results. However, he became more reticent than before the onset, and the others had recovered compared with those before the poisoning.

3. Discussing

To our knowledge, this is the first report of 5-amino-2-(trifluoromethyl)pyridine poisoning. Previously, few reports have described this compound. Its chemical structure is similar to that of aniline [2], which is oxidized into phenylhydroxylamine analogs after entering the human body, thereby causing methemoglobinemia, hemolytic anemia, abnormal liver and kidney function, and nervous system damage [4,5]. Our patient experienced similar symptoms, and laboratory findings confirmed the diagnosis of methemoglobinemia [6]. Therefore, based on its chemical structure and on the patient’s clinical manifestations, we hypothesized that 5-amino-2-(trifluoromethyl)pyridine oxidizes as hemoglobin to Met-Hb, as well as causing kidney and nervous system damage.

Methemoglobinemia occurs due to the oxidation of ferrous ions in erythrocytes to iron ions, resulting in excessive Met-Hb levels that cannot assure oxygen transport, thereby causing tissue hypoxia and damage [7,8]. Patients present with diffuse cyanosis and chocolate-colored arterial blood [9], and this hypoxia is difficult to ameliorate with oxygen. For these symptoms, MB is known to exert a curative effect. MB is an oxidant with two different effects on hemoglobin depending on its concentration in the body. At low concentrations, the hydrogen ions generated during glucose-6-phosphate dehydrogenation are transferred to MB through the reduction of pyridine nucleoside triphosphates, producing white methylene. Methylene white in turn reduces methemoglobin to normal hemoglobin [10]. High concentrations have the opposite effect, oxidizing normal hemoglobin to methemoglobin. Therefore, small doses (1–2 mg/kg) of MB should be given slowly intravenously during detoxification, as rapid and large doses will aggravate the symptoms of poisoning. Our patient quickly felt relieved of hypoxia following low-dose injection of methylene blue, showing that MB has a good effect on methemoglobinemia induced by 5-amino-2-(trifluoromethyl)pyridine. The patient developed hemolytic anemia and renal function damage due to tissue and cell hypoxia and damage caused by methemoglobinemia. Incidentally, 5-amino-2-(trifluoromethyl)pyridine is similar to aniline, which can reduce the production of reduced coenzyme II (NAD-PH) and inhibit the reduction of reduced glutathione (GSH), thereby rupturing red blood cells and causing hemolysis [11]. In such cases, high-dose steroids should be applied early on. However, if the condition cannot be effectively controlled even after high-dose steroid treatment, plasmapheresis can be performed to achieve good therapeutic effects [12,13].

On the 19th day of onset, the patient developed cognitive decline. MRI showed symmetrical hypointense signal on T1WI in the basal ganglia and corona radiata, and high signal on T2WI and DWI. The clinical and MRI findings were similar to those of delayed encephalopathy after acute carbon monoxide poisoning; however, the MRI findings are also similar to those of toxic encephalopathy caused by organic solvents including extensive white matter density reduction, symmetrical distribution, and no placeholder effect [14,15]. The chemical structure of 5-amino-2-(trifluoromethyl)pyridine is similar to aniline, which can cause neurological damage. However, the patient was comatose and experienced hypoxia for up to 10 h, and the possibility of delayed encephalopathy due to hypoxia could not be ruled out [16]. However, immediate removal, timely treatment of methemoglobinemia, and hypoxia correction are key to improve the overall patient prognosis, irrespective of the cause of toxic encephalopathy [6,17].
4. Conclusions

In conclusion, 5-amino-2-(trifluoromethyl)pyridine is toxic to the human body and can be absorbed through the respiratory tract; it can cause methemoglobinemia and hemolytic anemia. In our patient, both acute renal failure and delayed encephalopathy were observed. MB is effective in treating methemoglobinemia caused by 5-amino-2-(trifluoromethyl)pyridine poisoning. Early use of MB can treat methemoglobinemia and improve the patient prognosis.

Author Contributions: Y.L. and X.J. obtained research funding and investigated the description of the incident. Y.T. and J.H. conceived the study. Y.T., J.H. and L.S. supervised data collection, drafted the manuscript. Y.L. and X.J. take responsibility for the paper as a whole. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by the Beijing medical and health foundation (Grant no. YWJKJHZKJYJ-BXS5-22001) and the Chen Xiao-ping Foundation for the Development of Science and Technology of Hubei Province (Grant no. CXPJH12000005-07-40).

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki, and approved by the Ethics Committee of Qilu Hospital of Shandong University (protocol code: KLYY-2019-296 and approval date: 25 February 2019).

Informed Consent Statement: Informed consent was obtained for publication of this case report from the patient.

Data Availability Statement: The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author/s.

Conflicts of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References
1. National Center for Biotechnology Information. PubChem Compound Summary for CID 2737744, 5-Amino-2-(Trifluoromethyl)Pyridine. 2022. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/2737744 (accessed on 24 August 2022).
2. Armitage, I.; Fu, M.; Hicks, F.; Kattuboina, A.; Li, J.S.N.; McCarron, A.; Zhu, L. The use of Chloroformamidine hydrochloride as a reagent for the synthesis of guanidines from electron deficient aromatic amines. J. Heterocycl. Chem. 2017, 54, 728–734. [CrossRef]
3. Debenham, S.D.; Chan, A.; Liu, K.; Price, K.; Wood, H.B. A convenient one-pot synthesis of 4-, 6-, and 7-azaindoles from aminopyridines. Tetrahedron Lett. 2005, 46, 2283–2285. [CrossRef]
4. Iwersen-Bergmann, S.; Schmoldt, A. Acute intoxication with aniline: Detection of acetalaminophen as aniline metabolite. Int. J. Legal Med. 2000, 113, 171–174. [CrossRef] [PubMed]
5. Harvey, J.W.; Keitt, A.S. Studies of the efficacy and potential hazards of methylene blue therapy in aniline-induced methaemoglobinemia. Br. J. Haematol. 1983, 54, 29–41. [CrossRef] [PubMed]
6. Iolascon, A.; Bianchi, P.; Andolfo, I.; Russo, R.; Barcellini, W.; Fermo, E.; Toldi, G.; Ghirardello, S.; Rees, D.; Van Wijk, R.; et al. Recommendations for diagnosis and treatment of methemoglobinemia. Am. J. Hematol. 2021, 96, 1666–1678. [CrossRef] [PubMed]
7. Shi, L.; Yu, G.; Zhao, L.; Wen, Z.; Li, Y.; Kan, B.; Jian, X. Methemoglobinemia and delayed encephalopathy after 5-Bromo-2-Nitropyridine poisoning: A rare case report. Front. Public Health 2022, 10, 942003. [CrossRef] [PubMed]
8. Wright, R.O.; Lewander, W.J.; Woolf, A.D. Methemoglobinemia: Etiology, pharmacology, and clinical management. Ann. Emerg. Med. 1999, 34, 646–656. [CrossRef]
9. Cannata, G.; Abate, L.; Scabellato, C.; Rubini, M.; Giacometti, A.; Principi, N.; Esposito, S.; Dodi, I. The dose makes the poison: A case report of acquired methemoglobinemia. Int. J. Environ. Res. Public Health 2020, 17, 1845. [CrossRef] [PubMed]
10. D’sa, S.R.; Victor, P.; Jagannati, M.; Sudarsan, T.I.; Carey, R.A.B.; Peter, J.V. Severe methemoglobinemia due to ingestion of toxicants. Clin. Toxicol. 2014, 52, 897–900. [CrossRef] [PubMed]
11. Centers for Disease Control and Prevention (CDC). Severe methemoglobinemia and hemolytic anemia from aniline purchased as 2C-E (4-ethyl-2,5-dimethoxyphenethylamine), a recreational drug, on the Internet—Oregon. Morb. Mortal. Wkly. Rep. 2012, 61, 85–88.
12. Yiming, T.; Jie, H.; Yongsheng, L. Autoimmune hemolytic anemia in patients with relapsed Hodgkin’s lymphoma after treatment with penpulimab, a monoclonal antibody against programmed death receptor-1. Investag. New Drugs 2022, 40, 854–857. [CrossRef]
13. Mele, C.; Remuzzi, G.; Noris, M. Hemolytic uremic syndrome. Semin. Immunopathol. 2014, 36, 399–420. [CrossRef] [PubMed]
14. Chang, K.H.; Han, M.H.; Kim, H.S.; Wie, B.A.; Han, M.C. Delayed encephalopathy after acute carbon monoxide intoxication: MR imaging features and distribution of cerebral white matter changes. Radiology 1992, 184, 117–122. [CrossRef] [PubMed]
15. Wen, Z.; Dai, P.; Zhou, Z.; Guo, L.; Zhang, T.; Genjiafu, A.; Jian, T.; Li, Y.; Kan, B.; Jian, X. Case Report: Toxic encephalopathy caused by repeated inhalation of liquid sealant. *Front. Public Health* 2022, 10, 920310. [CrossRef] [PubMed]

16. Swor, D.E.; Sharp, F.R.; Jickling, G.C. Clinical Reasoning: A case of altered mental status, not otherwise specified. *Neurology* 2017, 89, e154–e158. [CrossRef] [PubMed]

17. Mak, R.S.P.; Liebelt, E.L. Methylene blue: An antidote for methemoglobinemia and beyond. *Pediatr. Emerg. Care* 2021, 37, 474–477. [CrossRef]